Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Kansas Cancer Center
mi
from
Fairway, KA
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
North Mississippi Hematology and Oncology Associates at BridgePoint
mi
from
Tupelo, MS
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
North Mississippi Hematology and Oncology Associates at BridgePoint
mi
from
Tupelo, MS
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Kansas City VA Medical Center
mi
from
Kansas City, MO
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Kansas City VA Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Richmond University Medical Center
mi
from
Staten Island, NY
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Richmond University Medical Center
mi
from
Staten Island, NY
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Medical Center
mi
from
Knoxville, TN
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Medical Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Lynchburg Hematology-Oncology Clinic
mi
from
Lynchburg, VA
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Lynchburg Hematology-Oncology Clinic
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Vince Lombardi Cancer Clinic
mi
from
Green Bay, WI
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Vince Lombardi Cancer Clinic
mi
from
Green Bay, WI
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA With or Without Minimally Invasive Surgery for Stage III and Stage IV (Oligometastatic) Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA With or Without Minimally Invasive Surgery for Stage III and Stage IV (Oligometastatic) Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ogden, UT
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Szczecin,
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Szczecin,
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Medical Center of Aurora
mi
from
Aurora, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Medical Center of Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Colorado Blood Cancer Institute
mi
from
Denver, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rose Medical Center
mi
from
Denver, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center
mi
from
Durango, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center
mi
from
Durango, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Southwest Oncology PC
mi
from
Durango, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Southwest Oncology PC
mi
from
Durango, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Care and Research Institute of Colorado LLC
mi
from
Englewood, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Care and Research Institute of Colorado LLC
mi
from
Englewood, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Englewood, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Mountain Blue Cancer Care Center
mi
from
Golden, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Mountain Blue Cancer Care Center
mi
from
Golden, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
North Colorado Medical Center
mi
from
Greeley, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers-Greenwood Village
mi
from
Greenwood Village, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Greenwood Village
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers-Lakewood
mi
from
Lakewood, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Lakewood
mi
from
Lakewood, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Anthony Hospital
mi
from
Lakewood, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Anthony Hospital
mi
from
Lakewood, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Littleton Adventist Hospital
mi
from
Littleton, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Littleton Adventist Hospital
mi
from
Littleton, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Littleton
mi
from
Littleton, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Littleton
mi
from
Littleton, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers-Sky Ridge
mi
from
Lone Tree, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Sky Ridge
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials